Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-10-19

Clinical Trial Update: Phase I/II Study of SRP-4053 in DMD Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study update for SRP-4053 in Duchenne Muscular Dystrophy completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SRP-4053

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Duchenne Muscular Dystrophy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-10-19